W

ill a change at the top of the US Securities and Exchange Commission mean that drug makers will not be so readily fined for paying bribes overseas as they seek to boost sales of their medicines?

Such speculation emerged after the Trump transition team last week tapped Jay Clayton, a partner at the Sullivan & Cromwell law firm, to head the agency. And the chatter about his views on the Foreign Corrupt Practices Act stems from a 2011 paper written by a New York City Bar Association committee, which he chaired, that maintained the law was causing “lasting harm” to US companies.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories